ALK and lung carcinoma: Among TKIs, ALK inhibitors have achieved the longest survival in patients on systemic treatment for advanced lung cancer, with a median OS exceeding 80 months [2], even with the presence of severe predictive and prognostic factors at baseline, such as brain metastases or aggressive co-mutations.